The case for & against
Bull & Bear analysis
Bearish
FOXO Technologies Inc. (NYSE: FOXO) is a pioneering life sciences company focused on leveraging epigenetic biomarkers for applications in health and longevity, primarily targeting the life insurance industry. The firm aims to disrupt traditional underwriting practices through innovative solutions, including the utilization of artificial intelligence and non-invasive saliva testing. Positioned within the burgeoning field of longevity science, FOXO seeks to align the interests of consumers and insurers by optimizing health data application in underwriting processes.
Bull says
- ↑Q2 net loss down 41% YOY to $13.8M, reflecting streamlined costs
- ↑Adjusted EBITDA improved to -$3.3M from -$4.5M YOY
- ↑Strategic pivot into bioinformatics and wellness markets estimated at $92B–$1.5T
- ↑Non-invasive saliva test could disrupt life insurance underwriting
- ↑High revisions and momentum factors indicate rising analyst expectations
- ↑QS Score suggests positive long-term qualitative outlook
Bear says
- ↓FY 2022 net loss widened to $95.3M from $38.5M, driven by higher expenses
- ↓Profitability factors remain deeply negative, undermining return generation
- ↓High short interest reflects investor skepticism on future performance
- ↓Success hinges on R&D outcomes, delaying product rollout and revenue streams
- ↓Stagnant growth factors and rising competition threaten market adoption
- ↓Weak earnings yield and operational efficiency deter long-term investment
Earnings Call · Q4 2022 · Mgmt. Guidance
Updated 09-07-2026neutral
Transcript signals
Bull points
- Many, if not most, of the leading causes of death occur as we age. And unsurprisingly, there are scientifically identifiable biological mechanisms behind this.
- As we begin to understand the biological science behind aging, we may in fact be able to stave off disease stay healthier for longer, and live longer.
- We believe this technology can revolutionize the insurance industry by aligning the interests of insurance companies, their agents, and consumers.
Bear points
- net loss was $95.3 million, or $8.40 per share, compared with a net loss of $38.5 million, or $6.61 per share during the same period in 2021.
- Increases in operating expenses drove nearly half of the increase in net loss with a large portion related to equity-based compensation.
- For the year ended December 31st, 2022, adjusted EBITDA was negative 19.8 million compared with adjusted EBITDA of negative 15 million during the same period in 2021.
Read full transcript analysis ›